Esperion Therapeutics (ESPR) Retained Earnings (2018 - 2025)
Historic Retained Earnings for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to -$1.7 billion.
- Esperion Therapeutics' Retained Earnings fell 669.94% to -$1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 billion, marking a year-over-year decrease of 669.94%. This contributed to the annual value of -$1.6 billion for FY2024, which is 333.99% down from last year.
- According to the latest figures from Q3 2025, Esperion Therapeutics' Retained Earnings is -$1.7 billion, which was down 669.94% from -$1.7 billion recorded in Q2 2025.
- In the past 5 years, Esperion Therapeutics' Retained Earnings ranged from a high of -$928.2 million in Q1 2021 and a low of -$1.7 billion during Q3 2025
- In the last 5 years, Esperion Therapeutics' Retained Earnings had a median value of -$1.5 billion in 2023 and averaged -$1.4 billion.
- As far as peak fluctuations go, Esperion Therapeutics' Retained Earnings crashed by 4977.13% in 2021, and later crashed by 333.99% in 2024.
- Over the past 5 years, Esperion Therapeutics' Retained Earnings (Quarter) stood at -$1.1 billion in 2021, then decreased by 21.12% to -$1.3 billion in 2022, then decreased by 15.62% to -$1.5 billion in 2023, then fell by 3.34% to -$1.6 billion in 2024, then decreased by 5.28% to -$1.7 billion in 2025.
- Its last three reported values are -$1.7 billion in Q3 2025, -$1.7 billion for Q2 2025, and -$1.6 billion during Q1 2025.